
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of **March 2015**

Commission File Number: **001-36187**

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street
Park Rehovot P.O.B 2100
Rehovot 7612002 Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 A Slide Presentation for Investors – March 2015.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.
(Registrant)

Date: March 2, 2015

By: /s/ Sigal Fattal

Sigal Fattal
Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NO. DESCRIPTION

99.1 A Slide Presentation for Investors – March 2015.



Introduction to Evogene

Ofer Haviv, President & CEO
March, 2015



Safe Harbor Statement

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

Evogene at a glance

Our mission	<ul style="list-style-type: none"> ■ Leader in the improvement of crop productivity and economics for the food, feed and biofuel industries
Products and end-markets	<ul style="list-style-type: none"> ■ Seed traits: improve traits underlying crops performance through biotechnology or breeding <ul style="list-style-type: none"> • Yield improvement: \$5 - \$7 billion market • Insect and disease resistance: \$7.5 - \$8.5 billion market ■ Seed external: address the need for innovative chemicals solutions, initially through herbicides <ul style="list-style-type: none"> • Novel herbicide: \$5.5 - 7.5 billion ■ Seeds: address the need for second generation feedstock for biofuels and industrial uses with castor <ul style="list-style-type: none"> • Industrial uses (shorter term): \$600 million market • Biofuels (longer term): \$18 billion market
What we do	<ul style="list-style-type: none"> ■ Identify, validate and license genes to improve seed traits, ■ Identify potential chemical molecules that can be "new modes of action" for herbicides ■ Transform castor into a modern, large scale economic feedstock for biofuel
Potential revenue sources	<ul style="list-style-type: none"> ■ Short to medium term: R&D and milestone payments from partners; castor seed sales ■ Long-term: royalties from seed traits and novel ag-chemical solutions
Core competencies	<ul style="list-style-type: none"> ■ Fundamental understanding of plant genomics and biology ■ Unique proprietary computational platforms and scientific expertise for genomic discoveries ■ Addressing the agriculture's bottleneck of integrating and analyzing big data
Partnership model	<ul style="list-style-type: none"> ■ Collaborations with industry leaders <div style="text-align: center;">        </div>

Introducing Evogene



The challenge and opportunity

The challenge: producing more with less

World population



Arable land per capita



The solution: increasing plant productivity and performance

Improved Seed Traits

1. Biotechnology
2. Advanced breeding

Seed External Solutions

1. Ag-chemicals
2. Ag-biologicals

The opportunity: utilizing genomics to improve plant productivity



► Our technology

Combining deep scientific understandings of genomics and proprietary computational capabilities, to leverage agriculture related 'big data' for prediction and validation of new products


Our unique position - solving the industry bottleneck



Agriculture is becoming heavily digitized, creating a tremendous opportunity for innovation-based products

Our technology platform

Combining computational power and plant science



Target markets and offering

▶ Target markets

1. Improved seed traits:

- biotech seeds (~\$20bn) and conventional seeds (~\$19bn)

2. Seed external:


- ag-chemicals (~\$54bn)

3. Proprietary seeds (Evofuel):

- castor for industry uses (\$600m) and as second generation feedstock for biofuels (~\$18bn)




Strategic position in plant genomics



1. Seed traits - yield & abiotic stress

Current product program pipeline



Potential near-term catalysts as more genes advance to Phase 2

Note: Any results, estimates, or calculations relating to probability of success at each phase of development may differ from company to company and across products. Furthermore, any such results, estimates, calculations, or probabilities may differ depending on a range of varying factors, including, but not limited to, market conditions, changing regulations or longer than expected regulatory processes, the traits and the crops that are the target of research or collaboration and the amount of resources available, or devoted to, particular research or collaboration projects by us or our collaborators.

Example - collaboration with Monsanto

Focus on yield and abiotic stress - Aug. 2008, extended Nov. 2011 and Oct. 2013




- 8 Year collaboration
- Traits - **yield**, drought tolerance, fertilizer utilization
- Biotic stress traits - **Fusarium** resistance
- Crops - **corn⁽¹⁾**, soybean, cotton, canola
- c.\$68m in R&D and up-front payments by Monsanto over collaboration period
- Milestone payments + royalties based on sales
- Equity investment in Evogene - \$30m (including \$12m in recent IPO)

Evogene New Gene Optimization Program Being Incorporated into Yield & Environmental Stress Collaboration with Monsanto

February 4th, 2015

Addition of new capabilities follows entry of more than 1,000 Evogene identified and validated candidate genes to Monsanto's product development pipeline

REHOVOT, ISRAEL – February 4, 2015 – Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today that its recently developed comprehensive gene optimization program is being incorporated into its multi-year collaboration with Monsanto Company. The addition of these new capabilities, which have been designed to optimize desired trait efficacy and potentially accelerate product development, follows the successful identification and validation by Evogene of more than one thousand genes that have entered Monsanto's product development pipeline. The collaboration, which was initiated in 2008 and extended in 2013, is focused on transgenic approaches for improved yield and enhanced stress tolerance in corn, soybean, cotton and canola. Genes that have been identified under the collaboration represent an important component of Monsanto's yield and environmental stress research and development program.




(1) Fusarium resistance activities are only in corn.

2. Seed traits - biotic stress

Current product program pipeline



Crop	Trait	Partner	Discovery	Phase 1	Phase 2	Phase 3	Phase 4
Corn	1. Fusarium	MONSANTO		<div style="width: 50%;"></div>			
	2. Rootworm			<div style="width: 50%;"></div>			
	3. Lygus hesperus	Marrone BioInnovations					
Soybean	4. Asian Rust	DUPONT		<div style="width: 50%;"></div>			
	5. Nematode	syngenta		<div style="width: 75%;"></div>			
Banana	6. Aphids			<div style="width: 50%;"></div>			
	7. Black Sigatoka	2B2A		<div style="width: 25%;"></div>	<div style="width: 75%;"></div>		
Cotton	8. Beet Armyworm	Marrone BioInnovations		<div style="width: 25%;"></div>	<div style="width: 75%;"></div>		



Note: Any results, estimates, or calculations relating to probability of success at each phase of development may differ from company to company and across products. Furthermore, any such results estimates, calculations, or probabilities may differ depending on a range of varying factors, including, but not limited to, market conditions, changing regulations or longer than expected regulatory processes, the traits and the crops that are the target of research or collaboration and the amount of resources available, or devoted to, particular research or collaboration projects by us or our collaborators.

3. Seed external - agriculture chemicals

Markets and key areas of focus



- Activities initiation - 2012
 - On-going internal program -
 - Target discovery & validation, initial hits
- Facilities, technology, personnel
- Seeking collaboration - major ag-player


Unique approach: biology to drive herbicide discovery



Ag-chemicals : robust market

- Crossed \$54 billion

- Current focus – herbicides
- Accounts for 44%
- Steady increase
- Strong need for innovation



- No new “mode of action” discovered in > 20 years

Source: Phillips McDougall, 2013

Evogene Introduces Biology Driven Ag-Chemical Discovery Platform

Rehovot, Israel - February 24, 2015 -

Platform to be initially applied to company's discovery program for novel herbicides -

Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today the introduction of its biology-driven platform for the discovery of novel ag-chemicals, with the initial application focused on novel herbicides. The ag-chemical discovery platform includes a new chemical-discovery computational platform, PointHit, and follows the announcement last year of Evogene's target-discovery computational platform, PointTar. Together, these two platforms, along with a uniquely designed chemical database also being announced today, provide a start-to-end discovery infrastructure for Evogene's rapidly growing ag-chemical program.




PointHit™




PointTar™

Our proposition

Targeting three multi-billion dollar markets



Strategic position in plant genomics



4. Seeds (castor)



- Activities initiated in 2007
- Established in 2012 as a wholly owned subsidiary
- Full license to all relevant Evogene technologies
- Primary product - castor bean seeds

Huge market potential

Short term use:

- Existing industries: biopolymers, lubricants, paints, etc.

Long term use:

- Second generation feedstock for biodiesel

Commercial production expected in 2016

- Key markets: Brazil and Argentina
- >5 million ha. potential for castor large scale production in Brazil
- Downstream strategic partnerships in target markets



leading agribusiness, 340,000 ha. in Brazil



leading biodiesel producer in Argentina

Evogene Subsidiary and SLC Agricola Sign Collaboration Agreement for Commercial Production of Castor Bean in Brazil

March 25th, 2014



Sales of castor bean grain under the collaboration are expected in 2016

Evogene Ltd. (NYSE: TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, and SLC Agricola S.A. (Bovespa: SLCE3; ADR's: SLCJY; Bloomberg: SLCE3 BZ; Reuters: SLCE3 SA), one of Brazil's largest landowners and agriculture businesses, announced today the signing of a collaboration agreement between SLC and Evofuel Ltd., Evogene's wholly-owned subsidiary, for the commercial production of Evofuel developed castor bean varieties in Brazil, expected to take place during 2016. Evofuel focuses on the development of high yielding castor bean seeds as a second-generation feedstock for the growing biofuel and other industrial markets.

Evogene Subsidiary and Embrapa to Cooperate on Advancing Castor Cultivation in Brazil

October 20th, 2014



The joint work will focus on research of castor disease control and best practices for soybean-castor crop rotation

The Brazilian Agricultural Research Corporation (Embrapa), Brazil's leading agricultural research institution, and Evogene Ltd. (NYSE: TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed, and biofuel industries, announced today the signing of a joint research agreement between Embrapa and Evofuel Ltd., Evogene's wholly-owned subsidiary, for the advancement of castor cultivation in Brazil. The cooperation will primarily focus on technologies for controlling castor-specific diseases as well as practices for castor cultivation in rotation with soybean.

CNH Industrial and Evogene Subsidiary Announce Ongoing Collaboration for the Development of a Mechanized Harvesting Solution for Castor Beans

December 15th, 2014



The collaboration, initiated two years ago, focuses on developing a customized combine for the efficient, large-scale harvesting of castor beans in Latin America

Rehovot, Israel – December 15, 2014 - Evogene Ltd. (NYSE: TASE: EVGN) and CNH Industrial Latin America Ltda., a subsidiary of CNH Industrial N.V. (NYSE: M; CNHI), announce today the ongoing cooperation between CNH Industrial and Evofuel Ltd., Evogene's wholly-owned subsidiary. This cooperation involves the development of an efficient, easy-to-adopt combine solution for the large-scale harvesting of Evofuel castor bean varieties in Latin America. The collaboration between CNH Industrial and Evofuel was initiated in 2012 and has recently been extended for an additional year.


Core revenue model and partnerships

► Business model & partners

- **Initial revenues:** R&D and milestone payments from partners; castor seed sales
- **Primary long-term revenues:** royalties from seed traits and ag-chemicals
- **Collaborations** with world leading agriculture companies



Our core revenue model



Note: Timing and trigger of milestone payments may vary between agreements.

Corporate information

Corporate Identity

- Key milestones:
 - 2002 - Spins off from Compugen (NASDAQ:CGN)
 - 2007 - lists on TASE (EVGN) ~\$34m (gross proceeds)
 - 2013 - lists on NYSE (EVGN) ~\$85m (gross proceeds)
- Market cap ~\$260m,
- shares outstanding ~25m
- ~200 FTEs, over 80% R&D positions

Cash position (December 31, 2014)

- ~\$116m in cash, short term bank deposits and marketable securities
- Operating cash burn for FY14 \$13.5m
- No long-term debt

(1) As of February 10, 2015

Evogene Presentation Subject



Thank You.
